# US 2019/0167776 A1 · Camkk2 inhibitor compositions and methods of using the same > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2019/0167776 A1 - Document ID: US20190167776A1 - Status: Published application - Kind: A1 - Application number: 16/323,482 - Filed: 2017-08-07 - Published: 2019-06-06 - Earliest claimed: 2016-08-05 - Assignees: Duke University - Applicants: Duke University - Inventors: Luigi RACIOPPI; Erik NELSON; Wei HUANG; Nelson CHAO; Donald MCDONNELL - Web page: https://patentgrep.com/patent/US20190167776A1 ## CPC - G01N 33/57515: of the breast - A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00) - A61K 39/001129: {Molecules with a "CD" designation not provided for elsewhere} - A61P 35/00: Antineoplastic agents - G01N 33/56972: {White blood cells} - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - G01N 2800/50: Determining the risk of developing a disease - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract Provided herein are compositions including a CaMKK2 inhibitor and an anti-cancer therapeutic agent and methods of treating cancer in a subject by administering a therapeutically effective amount of the composition to a subject. The subject may be selected for treatment based on an immune cell measurement of a sample from the subject. Methods of treating cancer by administering a therapeutically effective amount of a CaMKK2 inhibitor, and administering a therapeutically effective amount of an anti-cancer therapeutic agent to the subject are also provided. Kits including combination of a CaMKK2 inhibitor and another anti-cancer therapeutic agent are also provided. ## Claims ### Claim 1 A composition comprising a CaMKK2 inhibitor and an anti-cancer therapeutic agent. ### Claim 2 (depends on 1) A method of treating cancer in a subject comprising administering a therapeutically effective amount of the composition of claim 1 to the subject. ### Claim 3 A method of treating cancer in a subject comprising: obtaining a sample from the subject; measuring the immune cells in the sample; administering a CaMKK2 inhibitor to the subject. ### Claim 4 A method of treating cancer in a subject comprising administering to the subject a therapeutically effective amount of a CaMKK2 inhibitor provided that the subject was selected for treatment based on an immune cell measurement of a sample from the subject. ### Claim 5 (depends on 3) The method of claim 3, wherein the sample is a blood sample or tumor sample. ### Claim 6 (depends on 3) The method of claim 3, wherein the subject is administered the CaMKK2 inhibitor if the immune cell measurement in the sample is indicative of a poor prognosis or a likelihood of therapeutic resistance to an anti-cancer therapeutic agent. ### Claim 7 (depends on 3) The method of claim 3, further comprising providing an Immunoscore based on the immune cell measurement in the sample. ### Claim 8 (depends on 7) The method of claim 7, wherein the subject is administered the CaMKK2 inhibitor if the Immunoscore for the sample is 2 or below. ### Claim 9 (depends on 3) The method of any one of claim 3, further comprising administering an anti-cancer therapeutic agent to the subject. ### Claim 10 (depends on 1) A method of treating cancer comprising administering to the subject a therapeutically effective amount of the composition of claim 1 to the subject. ### Claim 11 (depends on 10) The method of claim 10, wherein the CaMKK2 inhibitor and the anti-cancer therapeutic agent are administered concurrently. ### Claim 12 (depends on 10) The method of claim 10, wherein the CaMKK2 inhibitor is administered at least one day prior to the anti-cancer therapeutic agent. ### Claim 13 (depends on 3) The method of claim 3, wherein the cancer comprises breast cancer. ### Claim 14 (depends on 3) The method of claim 3, wherein the subject is human. ### Claim 15 (depends on 1) A kit comprising the composition of claim 1. ### Claim 16 (depends on 3) The method of claim 3, wherein the CaMKK2 inhibitor is selected from the group consisting of an siRNA, a microRNA, an antibody, and a small molecule. ### Claim 17 (depends on 3) The method of claim 3, wherein the CaMKK2 inhibitor is selected from the group consisting of STO-609 and N28464-13-A1. ### Claim 18 (depends on 3) The method of claim 3, wherein the anti-cancer therapeutic agent is selected from the group consisting of a checkpoint inhibitor, a cancer vaccine, a T cell, an oncolytic virus, and a bispecific antibody. ### Claim 19 (depends on 3) The method of claim 3, wherein the anti-cancer therapeutic agent is selected from the group consisting of an Antigen-4 (CTLA-4) inhibitor, a programmed death-1/programmed death-ligands (PD-1/PD-L) inhibitor, and a T cell immunoglobulin mucin-3 (TIM-3) inhibitor. ### Claim 20 (depends on 3) The method of claim 3, wherein the anti-cancer therapeutic agent is selected from the group consisting of an anti-CTLA-4 antibody, an anti-PD-1 antibody, and an anti-PD-L1 antibody. ### Claim 21 (canceled) ### Claim 22 (canceled)